FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to medicine and concerns a stable composition of nanostructured Sildenafil inhibiting cyclic guanosine monophosphate (cGMP) specific phosphodiesterase type 5 (PDEV) containing a nanostructured Sildenafil base or its pharmaceutically acceptable salts having an average particle size of less than approximately 500nm, a stabilising agent, wherein the composition is prepared in a microfluidics-based continuous-flow tank reactor, and the composition possesses a semi-amorphous structure. The group of inventions also concerns a method for preparing the composition of nanostructured Sildenafil; using the above composition for preparing the pharmaceutical composition for treating male or female sexual dysfunction and pulmonary arterial hypertension.
EFFECT: group of inventions provides the improved solubility of the composition.
8 cl, 11 ex, 14 dwg
Title | Year | Author | Number |
---|---|---|---|
COMPOSITIONS OF TELMISARTAN IN FORM OF NANOPARTICLES, AND METHOD FOR PREPARING THEM | 2010 |
|
RU2526914C2 |
COMPOSITION OF NANOSTRUCTURED APREPITANT, SYNTHESIS METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | 2011 |
|
RU2595841C2 |
PHARMACEUTICAL COMPOSITION CONTAINING SILDENAFIL CITRATE, AND METHOD OF USING IT | 2013 |
|
RU2536425C2 |
PHARMACEUTICAL COMPOSITION | 2011 |
|
RU2589842C2 |
STABLE NON-AQUEOUS PHARMACEUTICAL COMPOSITIONS | 2008 |
|
RU2472492C2 |
EPOTILONE PHARMACEUTICAL DOSED FORMULATION FOR ORAL ADMINISTRATION | 2002 |
|
RU2291695C2 |
PHARMACEUTICAL COMPOSITION OF TAXOIDS | 2011 |
|
RU2603833C2 |
PHARMACEUTIC COMPOSITION INCLUDING ARBIDOL IN COMPOSITION OF PHOSPHOLIPID NANOPARTICLES | 2009 |
|
RU2411942C2 |
OXICODON AND NALOXON-CONTAINING PHARMACEUTICAL COMPOSITIONS WITH INSTANT RELEASE | 2010 |
|
RU2522212C2 |
CLEVIDIPINE NANOPARTICLES AND THEIR PHARMACEUTICAL COMPOSITIONS | 2015 |
|
RU2759673C2 |
Authors
Dates
2015-04-10—Published
2010-06-18—Filed